tradingkey.logo
tradingkey.logo
Search

Climb Bio Announces FDA Fast Track Designation For Budoprutug For The Treatment Of Primary Membranous Nephropathy

ReutersApr 7, 2026 11:10 AM

- Climb Bio Inc CLYM.O:

  • CLIMB BIO ANNOUNCES FDA FAST TRACK DESIGNATION FOR BUDOPRUTUG FOR THE TREATMENT OF PRIMARY MEMBRANOUS NEPHROPATHY

  • CLIMB BIO INC - TO SHARE INITIAL PHASE 2 DATA IN SECOND HALF OF 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI